Literature DB >> 26459093

Prevalence and spectrum of residual symptoms in Lyme neuroborreliosis after pharmacological treatment: a systematic review.

R Dersch1,2, H Sommer3, S Rauer4, J J Meerpohl5.   

Abstract

Controversy exists about residual symptoms after pharmacological treatment of Lyme neuroborreliosis. Reports of disabling long-term sequels lead to concerns in patients and health care providers. We systematically reviewed the available evidence from studies reporting treatment of Lyme neuroborreliosis to assess the prevalence and spectrum of residual symptoms after treatment. A literature search was performed in three databases and three clinical trial registers to find eligible studies reporting on residual symptoms in patients after pharmacological treatment of LNB. Diagnosis must have been performed according to consensus-derived case definitions. No restrictions regarding study design or language were set. Symptom prevalence was pooled using a random-effects model. Forty-four eligible clinical trials and studies were found: 8 RCTs, 17 cohort studies, 2 case-control studies, and 17 case series. The follow-up period in the eligible studies ranged from 7 days to 20 years. The weighted mean proportion of residual symptoms was 28 % (95 % CI 23-34 %, n = 34 studies) for the latest reported time point. Prevalence of residual symptoms was statistically significantly higher in studies using the "possible" case definition (p = 0.0048). Cranial neuropathy, pain, paresis, cognitive disturbances, headache, and fatigue were statistically significantly lower in studies using the "probable/definite" case definition. LNB patients may experience residual symptoms after treatment with a prevalence of approximately 28 %. The prevalence and spectrum of residual symptoms differ according to the applied case definition. Symptoms like fatigue are not reported in studies using the "probable/definite" case definition. As the "possible" case definition is more unspecific, patients with other conditions may be included. Reports of debilitating fatigue and cognitive impairment after LNB, a "post-Lyme syndrome", could therefore be an artifact of unspecific case definitions in single studies.

Entities:  

Keywords:  Fatigue; Lyme disease; Lyme neuroborreliosis; Prevalence review; Residual symptoms; Systematic review

Mesh:

Year:  2015        PMID: 26459093     DOI: 10.1007/s00415-015-7923-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  21 in total

1.  Evidence-based guidelines for the management of Lyme disease.

Authors:  Daniel Cameron; Andrea Gaito; Nick Harris; Gregory Bach; Sabra Bellovin; Kenneth Bock; Steven Bock; Joseph Burrascano; Constance Dickey; Richard Horowitz; Steven Phillips; Laurence Meer-Scherrer; Bernard Raxlen; Virginia Sherr; Harold Smith; Pat Smith; Raphael Stricker
Journal:  Expert Rev Anti Infect Ther       Date:  2004       Impact factor: 5.091

2.  Herpes simplex virus encephalitis: clinical manifestations, diagnosis and outcome in 106 adult patients.

Authors:  Uluhan Sili; Abdurrahman Kaya; Ali Mert
Journal:  J Clin Virol       Date:  2014-03-25       Impact factor: 3.168

3.  The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America.

Authors:  Gary P Wormser; Raymond J Dattwyler; Eugene D Shapiro; John J Halperin; Allen C Steere; Mark S Klempner; Peter J Krause; Johan S Bakken; Franc Strle; Gerold Stanek; Linda Bockenstedt; Durland Fish; J Stephen Dumler; Robert B Nadelman
Journal:  Clin Infect Dis       Date:  2006-10-02       Impact factor: 9.079

4.  Incidence of Lyme borreliosis in the Würzburg region of Germany.

Authors:  H I Huppertz; M Böhme; S M Standaert; H Karch; S A Plotkin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-10       Impact factor: 3.267

Review 5.  Lyme borreliosis.

Authors:  Gerold Stanek; Gary P Wormser; Jeremy Gray; Franc Strle
Journal:  Lancet       Date:  2011-09-06       Impact factor: 79.321

6.  Tick-borne encephalitis carries a high risk of incomplete recovery in children.

Authors:  Åsa Fowler; Lea Forsman; Margareta Eriksson; Ronny Wickström
Journal:  J Pediatr       Date:  2013-02-26       Impact factor: 4.406

7.  Perspectives on "chronic Lyme disease".

Authors:  Phillip J Baker
Journal:  Am J Med       Date:  2008-07       Impact factor: 4.965

8.  Lyme encephalopathy: long-term neuropsychological deficits years after acute neuroborreliosis.

Authors:  T Benke; T Gasse; M Hittmair-Delazer; E Schmutzhard
Journal:  Acta Neurol Scand       Date:  1995-05       Impact factor: 3.209

Review 9.  Practice parameters for the diagnosis of patients with nervous system Lyme borreliosis (Lyme disease). Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  J J Halperin; E L Logigian; M F Finkel; R A Pearl
Journal:  Neurology       Date:  1996-03       Impact factor: 9.910

Review 10.  Lyme disease: an infectious and postinfectious syndrome.

Authors:  E S Asch; D I Bujak; M Weiss; M G Peterson; A Weinstein
Journal:  J Rheumatol       Date:  1994-03       Impact factor: 4.666

View more
  22 in total

1.  Lyme Neuroborreliosis.

Authors:  Sebastian Rauer; Stefan Kastenbauer; Volker Fingerle; Klaus-Peter Hunfeld; Hans-Iko Huppertz; Rick Dersch
Journal:  Dtsch Arztebl Int       Date:  2018-11-09       Impact factor: 5.594

Review 2.  [Neuroborreliosis - Diagnostics, treatment and course].

Authors:  R Dersch; S Rauer
Journal:  Nervenarzt       Date:  2017-04       Impact factor: 1.214

3.  Enhanced Protective Immunogenicity of Homodimeric Borrelia burgdorferi Outer Surface Protein C.

Authors:  Diane G Edmondson; Sabitha Prabhakaran; Steven J Norris; Amy J Ullmann; Joe Piesman; Marc Dolan; Christian Probst; Christiane Radzimski; Winfried Stöcker; Lars Komorowski
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

4.  Association of Seropositivity to Borrelia burgdorferi With the Risk of Neuropsychiatric Disorders and Functional Decline in Older Adults: The Aging Multidisciplinary Investigation Study.

Authors:  Virgilio Hernández Ruiz; Arlette Edjolo; Claire Roubaud-Baudron; Benoît Jaulhac; José-Alberto Avila-Funes; Jean-François Dartigues; Hélène Amieva; Karine Pérès
Journal:  JAMA Neurol       Date:  2020-02-01       Impact factor: 18.302

5.  Cranial neuropathy and severe pain due to early disseminated Borrelia burgdorferi infection.

Authors:  Derek Ebner; Kelsey Smith; Daniel DeSimone; Muhammad Rizwan Sohail
Journal:  BMJ Case Rep       Date:  2018-01-23

6.  Neuroborreliosis.

Authors:  John J Halperin
Journal:  J Neurol       Date:  2016-11-24       Impact factor: 4.849

7.  Enhancement of cranial nerves in Lyme neuroborreliosis: incidence and correlation with clinical symptoms and prognosis.

Authors:  Elisabeth S Lindland; Anne Marit Solheim; Muhammad Nazeer Dareez; Randi Eikeland; Unn Ljøstad; Åse Mygland; Harald Reiso; Åslaug R Lorentzen; Hanne F Harbo; Mona K Beyer
Journal:  Neuroradiology       Date:  2022-05-24       Impact factor: 2.804

Review 8.  Persistent Symptoms After Treatment of Lyme Disease.

Authors:  Adriana Marques
Journal:  Infect Dis Clin North Am       Date:  2022-09       Impact factor: 5.905

9.  Cognitive function in patients with neuroborreliosis: A prospective cohort study from the acute phase to 12 months post treatment.

Authors:  Silje Andreassen; Anne Marit Solheim; Unn Ljøstad; Åse Mygland; Åslaug Rudjord Lorentzen; Harald Reiso; Mona Kristiansen Beyer; Hanne Flinstad Harbo; Gro Christine Christensen Løhaugen; Randi Eikeland
Journal:  Brain Behav       Date:  2022-05-20       Impact factor: 3.405

10.  Characterization of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidases from Borrelia burgdorferi: Antibiotic targets for Lyme disease.

Authors:  Kenneth A Cornell; Reece J Knippel; Gerald R Cortright; Meghan Fonken; Christian Guerrero; Amy R Hall; Kristen A Mitchell; John H Thurston; Patrick Erstad; Aoxiang Tao; Dong Xu; Nikhat Parveen
Journal:  Biochim Biophys Acta Gen Subj       Date:  2019-10-31       Impact factor: 3.770

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.